| Literature DB >> 32187355 |
Douglas B Cines1,2, Sergei Zaitsev1, Lubica Rauova3, Ann H Rux1, Victoria Stepanova1, Sriram Krishnaswamy3, Amrita Sarkar3, M Anna Kowalska3, Guohua Zhao3, Alan E Mast4,5, Laurence J Blumberg6, Keith R McCrae7,8, Mortimer Poncz3, Jonathan J Hubbard9, Michal Pyzik9,10, Richard S Blumberg8,9.
Abstract
Thromboembolism complicates disorders caused by immunoglobulin G (IgG)-containing immune complexes (ICs), but the underlying mechanisms are incompletely understood. Prior evidence indicates that induction of tissue factor (TF) on monocytes, a pivotal step in the initiation, localization, and propagation of coagulation by ICs, is mediated through Fcγ receptor IIa (FcγRIIa); however, the involvement of other receptors has not been investigated in detail. The neonatal Fc receptor (FcRn) that mediates IgG and albumin recycling also participates in cellular responses to IgG-containing ICs. Here we asked whether FcRn is also involved in the induction of TF-dependent factor Xa (FXa) activity by IgG-containing ICs by THP-1 monocytic cells and human monocytes. Induction of FXa activity by ICs containing IgG antibodies to platelet factor 4 (PF4) involved in heparin-induced thrombocytopenia (HIT), β-2-glycoprotein-1 implicated in antiphospholipid syndrome, or red blood cells coated with anti-(α)-Rh(D) antibodies that mediate hemolysis in vivo was inhibited by a humanized monoclonal antibody (mAb) that blocks IgG binding to human FcRn. IgG-containing ICs that bind to FcγR and FcRn induced FXa activity, whereas IgG-containing ICs with an Fc engineered to be unable to engage FcRn did not. Infusion of an α-FcRn mAb prevented fibrin deposition after microvascular injury in a murine model of HIT in which human FcγRIIa was expressed as a transgene. These data implicate FcRn in TF-dependent FXa activity induced by soluble and cell-associated IgG-containing ICs. Antibodies to FcRn, now in clinical trials in warm autoimmune hemolytic anemia to lower IgG antibodies and IgG containing ICs may also reduce the risk of venous thromboembolism.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32187355 PMCID: PMC7273830 DOI: 10.1182/blood.2019001133
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113